Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Published in: Haematologica
Access to document
10.3324/haematol.2019.243238
document
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP to improve the mCR rate. In a Phase I dose-escalation part in 12 patients, we showed that BV-DHAP is feasible. This Phase II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three 21-day cycles of BV 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin...
Marie José Kersten, Julia Driessen, Josée M Zijlstra, Wouter J Plattel, Franck Morschhauser, Pieternella J Lugtenburg, Pauline Brice, Martin Hutchings, Thomas Gastinne, Roberto Liu, Coreline N Burggraaff, Marcel Nijland, Sanne H Tonino, Anne I J Arens, Roelf Valkema, Harm van Tinteren, Marta Lopez-Yurda, Arjan Diepstra, Daphne De Jong, Anton Hagenbeek
Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Published in: Haematologica
Access to document
10.3324/haematol.2020.247536
document
Matthijs van der Meulen, Jacoline E C Bromberg, Marcel Nijland, Otto Visser, Jeanette K Doorduijn, Avinash G Dinmohamed
Machine Learning in the Differentiation of Follicular Lymphoma from Diffuse Large B-cell Lymphoma with Radiomic [18F]FDG PET/CT Features
Filipe Montes de Jesus, Yunchao Yin, Elissavet Mantzorou-Kyriaki, Xaver Kahle, Robbert de Haas, Derya Yakar, Andor W.J.M. Glaudemans, Walter Noordzij, Thomas Kwee, Marcel Nijland
Borrelia burgdorferi mimicking central nervous system relapse in diffuse large B cell lymphoma
Published in: Annals of Hematology
Access to document
10.1007/s00277-020-04022-5
document
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial
Published in: Haematologica
Access to document
10.3324/haematol.2019.238162
document
Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients withoutMYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in...
Martine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, Katerina Bakunina, Rogier Mous, Pieternella J Lugtenburg, Daan Dierickx, Gustaaf W van Imhoff, Joost S P Vermaat, Erik A F Marijt, Otto Visser, Caroline Mandigers, Yavuz M Bilgin, Aart Beeker, Mark F Durian, Bas van Rees, Lara H Bohmer, Lidwine W Tick, Rinske S Boersma, Tjeerd J F SnijdersHarry C Schouten, Harry R Koene, Eva de Jongh, Nathalie Hijmering, Arjan Diepstra, Anke van den Berg, Anne I J Arens, Julia Huijbregts, Otto Hoekstra, Josee M Zijlstra, Daphne de Jong, Marie José Kersten